Literature DB >> 30005832

Evaluation of a novel automatic screening tool for determining eligibility for a subcutaneous implantable cardioverter-defibrillator.

Rafi Sakhi1, Sing-Chien Yap1, Michelle Michels1, Arend F L Schinkel1, R Martijn Kauling1, Jolien W Roos-Hesselink1, Dominic A M J Theuns2.   

Abstract

BACKGROUND: The manufacturer has developed a new ECG screening tool to determine eligibility for the subcutaneous ICD (S-ICD), the "automatic screening tool" (AST), which may render manual ECG-screening unnecessary. The aim of the study was to determine the eligibility for the S-ICD using two methods (manual ECG-screening versus AST) in different patient categories including patients with cardiomyopathy, congenital heart disease and inherited primary arrhythmia syndrome.
METHODS: We prospectively evaluated the ECG suitability for an S-ICD in consecutive patients at our outpatient clinic between February and June 2017. The primary endpoint of the study was ECG eligibility defined as at least 1 successful vector in both supine and sitting postures.
RESULTS: A total of 254 patients (167 men; mean age 45 ± 16 years) were screened using both methods. Overall, there was a high ECG eligibility using either method (93% versus 92%, P = 0.45). Overall agreement between both methods was 94%. Patients with hypertrophic cardiomyopathy (HCM) more often had a failed screening test using either test in comparison to the patients without HCM (manual: odds ratio [OR] 3.3, 95% confidence interval [CI] 1.2-9.3, P = 0.02; AST: OR 3.0, 95% CI 1.2-7.6, P = 0.02).
CONCLUSION: AST showed a high agreement with manual ECG-screening for S-ICD. Overall there was a high ECG eligibility for S-ICD, although patients with HCM had a lower passing rate irrespective of the screening method.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Cardiomyopathy; Congenital heart disease; ECG; Inherited primary arrhythmia syndrome; Screening; Subcutaneous implantable cardioverter-defibrillator

Mesh:

Year:  2018        PMID: 30005832     DOI: 10.1016/j.ijcard.2018.07.037

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  2 in total

1.  Impact of SMART Pass filter in patients with ajmaline-induced Brugada syndrome and subcutaneous implantable cardioverter-defibrillator eligibility failure: results from a prospective multicentre study.

Authors:  Giulio Conte; Fabio Cattaneo; Carlo de Asmundis; Paola Berne; Alessandro Vicentini; Mehdi Namdar; Antonio Scalone; Catherine Klersy; Maria Luce Caputo; Andrea Demarchi; Tardu Özkartal; Francesca Salghetti; Gavino Casu; Ilaria Passarelli; Stefano Mameli; Dipen Shah; Haran Burri; Gaetano De Ferrari; Pedro Brugada; Angelo Auricchio
Journal:  Europace       Date:  2022-05-03       Impact factor: 5.486

2.  A novel screening test for inappropriate shocks due to myopotentials from the subcutaneous implantable cardioverter-defibrillator.

Authors:  Yuji Ishida; Shingo Sasaki; Yuichi Toyama; Kimitaka Nishizaki; Yoshihiro Shoji; Takahiko Kinjo; Taihei Itoh; Daisuke Horiuchi; Masaomi Kimura; Michael R Gold; Hirofumi Tomita
Journal:  Heart Rhythm O2       Date:  2020-04-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.